Detailed Information

Cited 2 time in webofscience Cited 2 time in scopus
Metadata Downloads

Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project

Authors
Lee, YoungwooLee, SoohyeonSung, Jae SookChung, Hee-JoonLim, Ah-reumKim, Ju WonChoi, Yoon JiPark, Kyong HwaKim, Yeul Hong
Issue Date
1월-2021
Publisher
KOREAN CANCER ASSOCIATION
Keywords
Colorectal neoplasms; Genomics; High-throughput nucleotide sequencing
Citation
CANCER RESEARCH AND TREATMENT, v.53, no.1, pp.123 - 130
Indexed
SCIE
SCOPUS
KCI
OTHER
Journal Title
CANCER RESEARCH AND TREATMENT
Volume
53
Number
1
Start Page
123
End Page
130
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/50620
DOI
10.4143/crt.2020.559
ISSN
1598-2998
Abstract
Purpose Next-generation sequencing (NGS) can facilitate precision medicine approaches in metastatic colorectal cancer (mCRC) patients. We investigated the molecular profiling of Korean mCRC patients under the K-MASTER project which was initiated in June 2017 as a nationwide precision medicine oncology clinical trial platform which used NGS assay to screen actionable mutations. Materials and Methods As of 22 January 2020, total of 994 mCRC patients were registered in K-MASTER project. Targeted sequencing was performed using three platforms which were composed of the K-MASTER cancer panel v1.1 and the SNUH FIRST Cancer Panel v3.01. If tumor tissue was not available, cell-free DNA was extracted and the targeted sequencing was performed by Axen Cancer Panel as a liquid biopsy. Results In 994 mCRC patients, we found 1,564 clinically meaningful pathogenic variants which mutated in 71 genes. Anti-EGFR therapy candidates were 467 patients (47.0%) and BRAF V600E mutation (n=47, 4.7%), deficient mismatch repair/microsatellite instability-high (n=15, 1.5%), HER2 amplifications (n=10, 1.0%) could be incorporated with recently approved drugs. The patients with high tumor mutation burden (n=101, 12.7%) and DNA damaging response and repair defect pathway alteration (n=42, 4.2%) could be enrolled clinical trials with immune checkpoint inhibitors. There were more colorectal cancer molecular alterations such as PIK3CA, KRAS G12C, atypical BRAF, and HER2 mutations and even rarer but actionable genes that approved or ongoing clinical trials in other solid tumors. Conclusion K-MASTER project provides an intriguing background to investigate new clinical trials with biomarkers and give therapeutic opportunity for mCRC patients.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Kyong Hwa photo

Park, Kyong Hwa
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE